Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Completed 4Terminated 3

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 4NET 1Genitourinary 1Dermatologic 1

Conditions

Neuroendocrine Tumors 6Carcinoid Tumor 5Acromegaly 5Pituitary Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Liver Neoplasms 2Growth Disorders 2Gigantism 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Thyroid Neoplasms 1Serotonin Syndrome 1Prolactinoma 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary ACTH Hypersecretion 1Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Dumping Syndrome 1Carcinoma, Neuroendocrine 1Carcinoma, Medullary 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma 1

Interventions

pasireotide 4Cabergoline 3Surgical Procedures, Operative 2Propofol 2Octreotide 2Human Growth Hormone 2pegvisomant 1entinostat 1corticorelin ovine 1Yoga 1Thyrotropin-Releasing Hormone 1Surveys and Questionnaires 1Supine Position 1Sevoflurane 1Resistance Training 1Radiotherapy 1Radiosurgery 1Photochemotherapy 1Nivolumab 1Neurosurgical Procedures 1Lapatinib 1Ipilimumab 1Ibuprofen 1Hydrocortisone 1Growth Hormone 1Dosage Forms 1Dihematoporphyrin Ether 1Dexamethasone 1Desflurane 1Continuous Glucose Monitoring 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Pituitary Neoplasms × pasireotide × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT02354508 2019-12-10

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Novartis

Phase 3 Completed
123 enrolled 27 charts
Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Novartis

Phase 2 Completed
33 enrolled 24 charts
Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01137682 2018-04-05

PAOLA

Novartis

Phase 3 Completed
198 enrolled 17 charts
Endocrine

Acromegaly, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡